JonesTrading analyst Boris Peaker has maintained their bullish stance on ELVN stock, giving a Buy rating on April 27.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Boris Peaker has given his Buy rating due to a combination of factors, primarily the strong clinical performance of ELVN-001 in chronic myeloid leukemia relative to existing therapies. Early Phase 1 data show major molecular response rates that substantially exceed current standard-of-care outcomes in later-line settings, suggesting a meaningful efficacy advantage that could translate into significant clinical uptake.
Peaker also highlights upcoming catalysts, including additional Phase 1 data in mid-2026 and the planned start of the pivotal Phase 3 ENABLE-2 trial in the second half of 2026, which together de-risk the development path. In addition, he views Enliven as an attractive strategic asset, noting Merck’s sizable acquisition of a key competitor as validation of the space and arguing that Enliven’s focused CML profile and promising data position it well for a potential future takeover.
In another report released on April 27, Clear Street also maintained a Buy rating on the stock with a $55.00 price target.